GENE ONLINE|News &
Opinion
Blog

Parkinson’s Disease
Aspen Neuroscience Rakes in $147.5 Million for Parkinson’s Cell Therapy Development
2022-05-10
4D Pharma Cleared to Investigate Healing the Brain through the Gut
2022-03-16
Abbvie Acquires Neuroscience Company Syndesi for $1 Billion
2022-03-02
Sanofi Licenses ABL Bio’s Bispecific Antibody for Parkinson’s Disease
2022-01-13
Novartis, UCB Take Aim at Parkinson’s Disease Under $1.65 Billion Collab
2021-12-03
South Korea’s D&D Pharmatech Secures $51M Series C, Eyes 2022 IPO
2021-10-20
M&A
Supernus Invests $400 Million to Acquire New Parkinson’s Assets from Adamas
2021-10-12
Voyager Encounters Regulatory Bump in Parkinson’s Trial
2020-12-25
First of its Kind Therapy for Parkinson’s Disease Advances to Phase 2b Trials
2020-10-22
Exploring RNA Splicing as a Potential New Drug Avenue for Parkinson’s Disease
2020-09-16
TET2 – A Master Switch to Turn off Parkinson Disease Symptoms
2020-08-22
R&D
Altering the Treatment Landscape of Neurodegenerative Diseases Using Antisense Oligonucleotides (ASOs)
2020-08-17
Weekly in Asia|SEP
2019-09-27
LATEST
Flagship-Backed ProFound Launches With $75 Million to Discover Human Proteins
2022-05-27
Janssen’s First Cell Therapy Gets Europe’s Approval for Multiple Myeloma
2022-05-27
Cell and Gene Therapy Landscape in Japan is Moving Beyond Oncology
2022-05-27
New Study Reveals Hope for Recovery of Patients with Spinal Cord Injury
2022-05-27
Laekna Therapeutics Announces Dosing of First Patients in the U.S. and China in Phase Ib/III Study of Afuresertib in Combination with Fulvestrant in HR+/HER2- Breast Cancer
2022-05-26
Stanford Touts Remote-Controllable CAR-T Cell Therapy
2022-05-26
Phenomix Launches The First Obesity Biobank Registry To Study Underling Phenotypes
2022-05-26
EVENT
2022-06-03
ASCO Annual Meeting
Online and on-side
2022-06-07
Digital RESI June
Online
2022-06-09
Medhospafrica
Africa
2022-06-13
BIO International Convention
San Diego, CA
2022-12-14
BIOHK2022
Hong Kong, China
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!